We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Xspray Pharma AB (XSPRAY) NPV

Sell:40.20 SEK Buy:40.45 SEK Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:40.20 SEK
Buy:40.45 SEK
Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:40.20 SEK
Buy:40.45 SEK
Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company. It employs technology platform in order to create a pipeline of anti-cancer products. The Company primarily develops protein kinase inhibitors (PKI) for targeted cancer treatments. The product candidates include Sprycel, also known as HyNap-Dasa, (version of dasatinib medicine), Tasigna, also under name HyNap-Nilo, (version of nilotinib medicine) and Nexavar, also is under name HyNap-Sora, (version of sorafenib medicine), among others. Sprycel and Tasigna are indicated for treatment of adult patients diagnosed with Philadelphia chromosome-positive (pH+) chronic myeloid leukemia (CML). Sprycel is also indicated for the treatment of adult patients with pH+ acute lymphocytic leukemia (ALL) and lymphoid blastic CML with resistance or intolerance to prior treatment. Nexavar is indicated for the treatment of patients with liver cell cancer, renal cell cancer and differentiated thyroid cancer.

Contact details

Address:
Rasundavagen 12
SOLNA
169 67
Sweden
Telephone:
+46 (8) 7303700
Website:
https://xspraypharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
XSPRAY
ISIN:
SE0009973563
Market cap:
1.01 billion SEK
Shares in issue:
31.25 million
Sector:
Biotechnology
Exchange:
Stockholm Stock Exchange
Country:
Sweden
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Anders Ekblom
    Chairman of the Board
  • Per Andersson
    Chief Executive Officer
  • Michael af Winklerfelt
    Acting Chief Financial Officer
  • Anette Abrahamsson
    Senior Vice President - Regulatory Affairs
  • Linda Glimberg
    Senior Vice President - Legal, Consultant
  • Christer Hallgren
    Senior Vice President - Intellectual Property
  • Charlotta Liljebris
    Senior Vice President - Research and Development
  • Kerstin Hasselgren
    Head of Investor Relations
  • Edward Jordan
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.